Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20488257 | 0.86 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL20487061 | 0.86 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL11949327 | 0.83 | KDM4E (0.30) | — | |
| SCHEMBL1804178 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1807600 | 0.74 | OPRL1 (0.38) | ALDH1A1 | |
| SCHEMBL25095531 | 0.73 | ESR1 (0.32) | — | |
| SCHEMBL20487416 | 0.71 | KDM4E (0.38) | SMN1; SMN2 | |
| SCHEMBL21681645 | 0.71 | RORC (0.36) | — | |
| SCHEMBL25359821 | 0.69 | — | — | |
| SCHEMBL25360774 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501704-B1 | Spiropiperidine compounds as oral-1 receptor antagagonisten | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2501703-B1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OXER1, OGFRL1, ORMDL3 | ALDH1A1 95/4885SMN1; SMN2 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.